Summit Therapeutics (SMMT) Prepaid Assets (2018 - 2026)
Summit Therapeutics' (SMMT) quarterly Prepaid Assets came in at $29.6 million in Q2 2026, up 167.74% YoY from $11.0 million in Q2 2025, and up 68.55% on a QoQ basis from $17.6 million in Q1 2026.
Summit Therapeutics (SMMT) Prepaid Assets (2018 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 9 years of Prepaid Assets data on file, last reported at $29.6 million in Q2 2026.
- Quarterly Prepaid Assets rose 167.74% year-over-year to $29.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $29.6 million (up 167.74% YoY) and the FY2025 annual result came in at $6.5 million, down 40.98% from the prior year.
- Prepaid Assets rose to $29.6 million in Q2 2026, from $17.6 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $29.6 million in Q2 2026 to a low of $1.2 million in Q1 2023.
- A 5-year average of $7.2 million and a median of $5.4 million in 2022 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets slumped 80.71% — and 2025, when it jumped 438.45%.
- Tracing SMMT's Prepaid Assets over 5 years: stood at $1.5 million in 2022, then surged by 74.34% to $2.6 million in 2023, then jumped by 322.43% to $11.1 million in 2024, then slumped by 40.98% to $6.5 million in 2025, then jumped by 352.55% to $29.6 million in 2026.
- The last three Prepaid Assets figures came in at $29.6 million (Q2 2026), $17.6 million (Q1 2026), and $6.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.58 Mn |
| Mar 31, 2026 | 17.55 Mn |
| Dec 31, 2025 | 6.54 Mn |
| Sep 30, 2025 | 7.59 Mn |
| Jun 30, 2025 | 11.05 Mn |
| Mar 31, 2025 | 9.12 Mn |
| Dec 31, 2024 | 11.08 Mn |
| Sep 30, 2024 | 2.41 Mn |
| Jun 30, 2024 | 2.05 Mn |
| Mar 31, 2024 | 5.32 Mn |
| Dec 31, 2023 | 2.62 Mn |
| Sep 30, 2023 | 5.07 Mn |
| Jun 30, 2023 | 6.09 Mn |
| Mar 31, 2023 | 1.19 Mn |
| Dec 31, 2022 | 1.50 Mn |
| Sep 30, 2022 | 1.62 Mn |
| Jun 30, 2022 | 5.39 Mn |
| Mar 31, 2022 | 4.35 Mn |
| Dec 31, 2021 | 7.16 Mn |
| Sep 30, 2021 | 8.41 Mn |